Business transacted at the annual general meeting of Aquaporin A/S

Aquaporin A/S, Nymøllevej 78, DK-2800 Kongens Lyngby, aquaporin.com, Company registration no.: DK28315694

Company announcement
No. 13/2024

Copenhagen, April 29, 2024 – Aquaporin A/S (ticker: AQP) (“Aquaporin” or the “Company”), an innovative water technology company dedicated to rethinking water filtration with biotechnology, today held its annual general meeting, at which the general meeting:

• Took note of the Board of Directors’ report on the Company’s activities in the past financial year;
• Adopted the annual report for 2023;
• Adopted the Board of Directors’ proposal to carry forward the loss for the financial year ended December 31, 2023, and that no dividend is paid to shareholders for the financial year ended December 31, 2023;
• Resolved to grant discharge of liability to the Board of Directors and the Executive Management;
• Approved the remuneration report for the past financial year in an advisory vote;
• Approved the remuneration for the Board of Directors for the current financial year and until the next annual general meeting;
• Re-elected Niels Heering, Søren Bjørn Hansen, Anne Broeng, Lars Hansen, Anupam Bhargava, Weiming Jiang, and Jianlong Zhuang and elected Peter Holme Jensen as members of the Board of Directors for a term of one year;
• Re-elected EY Godkendt Revisionspartnerselskab as auditor both in relation to financial reporting as well as in relation to sustainability reporting;
• Authorized the Board of Directors to acquire treasury shares in the period until April 29, 2028, on one or more occasions, with a total value of up to 10% of the Company’s share capital from time to time, subject to the Company’s holding of treasury shares after such acquisitions does not exceed 10% of the Company’s share capital. The consideration may not deviate more than 10% from the official price quoted on Nasdaq Copenhagen at the date of agreement or acquisition;
• Approved the proposal to amend the Articles of Association with a new Article 3.2 regarding a new authorization to the Board of Directors to increase the share capital without pre-emptive rights for existing shareholders at market price with up to nominally DKK 2,541,000 equal to approximately 11% of the current share capital until April 28, 2027;
• Approved the proposal to amend the Articles of Association with a new Article 3.3 regarding a new authorization to the Board of Directors to increase the share capital with pre-emptive rights for existing shareholders at or below market price with up to nominally DKK 2,541,000 equal to approximately 11% of the current share capital until April 28, 2027;
• Approved the proposal to delete the current Article 3.5 regarding the combined maximum for the authorizations to increase the share capital;
• Approved the proposal to update the Company’s current indemnification scheme for the Board of Directors and Executive Management. The Indemnification Scheme will cover claims arising out of circumstances or events having occurred after April 29, 2024 but no later than June 30, 2028;
• Approved the proposal to amend the Articles of Association with a new Article 12.1 to reflect the updated indemnification scheme for members of the Board of Directors and Executive Management;
• Approved the proposal to amend the Remuneration Policy with new sections 7.1 and 7.2 to reflected the updated indemnification scheme for members of the Board of Directors and Executive Management;
• Approved the Company’s full Remuneration Policy;
• Approved the proposal to amend the Articles of Association with a new Article 4.15.f to renew and increase the existing authorization to issue warrants in Article 4.15 by 1,078,106 warrants until April 28, 2029.

After the annual general meeting, the Board of Directors constituted itself and elected Niels Heering as Chair and Søren Bjørn Hansen as Deputy Chair.

For further information, please contact:

Matt Boczkowski, Chief Executive Officer

Klaus Juhl Wulff, Chief Financial Officer

+45 53 55 55 19, [email protected]

About Aquaporin A/S
Aquaporin is an innovative water technology company with operations in Denmark (HQ), Singapore, Turkey, the United States, and China. We are committed to rethinking water filtration with biotechnology to solve global water challenges. By combining three disciplines from the world of natural sciences: biology, chemistry, and physics, we have created the unique, nature-inspired Aquaporin Inside^® technology which we embed into all our membranes and solutions. Our technology is based on Nobel Prize-winning research and is used to clean and reuse water in industries, in our homes, and even by NASA in space. We work with customers and partners around the globe to responsibly treat industrial wastewater, concentrate food and beverage products in a natural way, and enhance drinking water quality and accessibility.

Forward-looking statements
Matters discussed in this company announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and that can be identified by words such as “believe”, “expect”, “anticipate”, “intend”, “estimate”, “will”, “may”, “continue”, “should”, and similar expressions, as well as other statements regarding future events or prospects. Specifically, this company announcement includes information with respect to projections, estimates, and targets that also constitute forward-looking statements. The forward-looking statements in this company announcement are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies, and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, and other important factors include, among others: Limited experience in commercialization of the Company’s products, failure to successfully implement strategies, dependence on third parties for manufacturing certain product components and the supply of certain raw materials,  manufacturing disruptions, strategic collaboration, protection of the Company’s intellectual property rights and other risks disclosed in Aquaporin’s annual reports, prospectuses and company announcements. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations, projections, estimates, and targets expressed or implied in this company announcement by such forward-looking statements. The information, opinions, and forward-looking statements contained in this company announcement speak only as at its date and are subject to change without notice. Aquaporin expressly disclaims any obligation to update or revise any forward-looking statements, except as required by law.